Additional analysis of the pros and cons of Johnson & Johnson’s COVID-19 vaccine, along with only a few new cases of rare blood clots, persuaded the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) to vote to lift the pause on its administration, a step it was not ready to take a week earlier.
With the extended stoppage now over, the question for sponsors and public health officials is what impact it will have...




